- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 09.09. | Xilio Therapeutics, Inc.: Xilio Therapeutics Announces Initiation of Phase 2 Trial for Efarindodekin Alfa (XTX301), a Tumor-Activated IL-12, and Achievement of $17.5 Million Development Milestone Under Exclusive License ... | 614 | GlobeNewswire (Europe) | Phase 1 data for efarindodekin alfa (XTX301) demonstrate promising anti-tumor activity in patients with advanced solid tumors Achievement of milestone extends anticipated cash runway into first... ► Artikel lesen | |
| 09.09. | Xilio Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 28.08. | Xilio Therapeutics, Inc. - 8-K, Current Report | 4 | SEC Filings | ||
| XILIO THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 14.08. | Xilio Therapeutics, Inc. - 10-Q, Quarterly Report | 4 | SEC Filings | ||
| 14.08. | Xilio Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 06.08. | Leerink Partners initiates coverage on Xilio Therapeutics stock with Outperform rating | 1 | Investing.com | ||
| 01.08. | Xilio Therapeutics, Inc.: Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 96 | GlobeNewswire (Europe) | WALTHAM, Mass., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies... ► Artikel lesen | |
| 02.07. | Xilio Therapeutics, Inc.: Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 119 | GlobeNewswire (Europe) | WALTHAM, Mass., July 02, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies... ► Artikel lesen | |
| 10.06. | Xilio Therapeutics erweitert Vorstand mit neuem Direktor | 2 | Investing.com Deutsch | ||
| 10.06. | Xilio Therapeutics, Inc.: Xilio Therapeutics Appoints Akintunde Bello, Ph.D., to its Board of Directors | 3 | GlobeNewswire (USA) | ||
| 10.06. | Xilio Therapeutics, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 06.06. | Xilio Therapeutics, Inc.: Xilio Therapeutics Announces Closing of $50.0 Million Public Offering | 2 | GlobeNewswire (USA) | ||
| 03.06. | Xilio Therapeutics, Inc.: Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 104 | GlobeNewswire (Europe) | WALTHAM, Mass., June 03, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies... ► Artikel lesen | |
| 02.06. | Xilio Therapeutics announces pricing of $50 million public offering | 2 | Seeking Alpha | ||
| 02.06. | Xilio Therapeutics, Inc.: Xilio Therapeutics Announces Pricing of $50.0 Million Public Offering | 1 | GlobeNewswire (USA) | ||
| 02.06. | Xilio Therapeutics announces public offering; shares down | 1 | Seeking Alpha | ||
| 02.06. | Xilio Therapeutics announces public offering of warrants | 1 | Investing.com | ||
| 02.06. | Xilio Therapeutics, Inc.: Xilio Therapeutics Announces Proposed Public Offering | 2 | GlobeNewswire (USA) | ||
| 02.06. | Xilio Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 01.06. | Xilio Therapeutics, Inc. (XLO) Reports 26% Response in Colon Cancer Drug Trial | 4 | Insider Monkey |
1 2 Weiter >>
39 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PALATIN TECHNOLOGIES | - | - | Boehringer Ingelheim Limited: Boehringer Ingelheim and Palatin Technologies to develop potential first-in-class melanocortin receptor targeted treatment for patients with retinal diseases | · Collaboration strengthens Boehringer's pipeline in Eye Health.· Many patients with diabetic retinopathy (DR) continue to experience vision loss or treatment fatigue, underscoring an... ► Artikel lesen | |
| BIOXXMED | 0,200 | 0,00 % | PTA-Adhoc: bioXXmed AG: Ergebnis für das Geschäftsjahr 2024 - Prognose für das Geschäftsjahr 2025 | DJ PTA-Adhoc: bioXXmed AG: Ergebnis für das Geschäftsjahr 2024 - Prognose für das Geschäftsjahr 2025
Veröffentlichung von Insiderinformationen gemäß Artikel 17 MAR
bioXXmed AG: Ergebnis für... ► Artikel lesen | |
| VIVOSIM LABS | 1,220 | -100,00 % | VivoSim Labs, Inc.: VivoSim Labs Appoints Tony Lialin as Chief Commercial Officer | SAN DIEGO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company" or "VivoSim Labs"), a pharmaceutical and biotechnology services company that is focused on providing testing... ► Artikel lesen | |
| OCUGEN | 1,155 | +0,83 % | Ocugen, Inc. and Kwangdong Pharmaceutical Co., Ltd. Complete License Agreement of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea | Upfront fees and near-term development milestone payments totaling up to $7.5 millionPotential sales milestones of $180 million or more in first 10 years of commercializationRoyalties equaling 25%... ► Artikel lesen | |
| SIRONA BIOCHEM | 0,037 | -100,00 % | Sirona Biochem Corp: Sirona Biochem downgraded to NEX | ||
| BIO-GATE | 1,090 | +12,37 % | Bio-Gate platziert Kapitalerhöhung über 836.059 neue Aktien | Die Bio-Gate AG hat eine Barkapitalerhöhung aus genehmigtem Kapital beschlossen und umgesetzt. Das Grundkapital wird von 9.243.691 Euro um 836.059 Euro auf 10.079.750 Euro erhöht. Dazu werden 836.059... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,467 | -2,51 % | Defence Therapeutics Inc.: Defence Therapeutics Appoints Dr. Amie Phinney as Director | Montreal, Quebec--(Newsfile Corp. - September 16, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a leading biotechnology company specialized in... ► Artikel lesen | |
| VAXART | 0,368 | +22,45 % | Vaxart, Inc.: Vaxart Announces Withdrawal of Reverse Stock Split Proposal | SOUTH SAN FRANCISCO, Calif., Sept. 19, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) ("Vaxart" or the "Company"), a clinical-stage biotechnology company developing a range of oral recombinant... ► Artikel lesen | |
| BURCON NUTRASCIENCE | 1,400 | -4,11 % | Burcon NutraScience Corporation: Burcon Announces New Board Members and Results of Shareholder Meeting | Vancouver, British Columbia--(Newsfile Corp. - September 17, 2025) - Burcon NutraScience Corporation (TSX: BU) (OTCQB: BRCNF) (the "Burcon" or the "Company"), a global technology leader in plant-based... ► Artikel lesen | |
| CELLECTAR BIOSCIENCES | 5,270 | -4,01 % | Cellectar Biosciences, Inc.: Cellectar Biosciences Reports Second Quarter 2025 Financial Results and Provides a Corporate Update | Intend to Pursue an NDA Submission to the U.S. FDA under Accelerated Approval Pathway for Iopofosine I 131 for the Treatment of Waldenstrom Macroglobulinemia (WM) Subject to Sufficient Funding and... ► Artikel lesen | |
| AFFIMED | 0,972 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 28.05.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 28.05.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 28.05.2025ISIN NameBMG3728V1090 GAN... ► Artikel lesen | |
| AIM IMMUNOTECH | 0,073 | 0,00 % | AIM ImmunoTech Inc.: AIM ImmunoTech Highlights Growing Body of Compelling Data of Ampligen for the Treatment of Pancreatic Cancer at Conference in Poland | Latest progress from lead program Ampligen for the treatment of pancreatic cancer highlighted at the International 5th Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care
Ampligen... ► Artikel lesen | |
| IMMUNIC | 0,721 | +1,41 % | EQS-News: Immunic AG: Immunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium's Dose Strengths in Progressive Multiple Sclerosis | Issuer: Immunic AG
/ Key word(s): Patent
Immunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium's Dose Strengths in Progressive Multiple... ► Artikel lesen | |
| T2 BIOSYSTEMS | 0,250 | 0,00 % | NSE/A - T2 Biosystems, Inc. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | ||
| CEL-SCI | 8,610 | -4,33 % | Original-Research: CEL-SCI Corporation (von First Berlin Equity Research GmbH): BUY | Original-Research: CEL-SCI Corporation - from First Berlin Equity Research GmbH
01.09.2025 / 13:38 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The issuer... ► Artikel lesen |
XILIO THERAPEUTICS INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von -0,012 (-1,60 %) liegt der Kurs bei 0,750 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu XILIO THERAPEUTICS INC finden Sie auf Wallstreet Online.